IDEAYA Biosciences Inc. (NASDAQ: IDYA) entered into a clinical collaboration with Roche to evaluate a combination therapy for patients with pancreatic ductal adenocarcinoma that carries specific genetic mutations.

The collaboration will test IDE892, IDEAYA's investigational PRMT5 inhibitor currently in Phase 1 trials, combined with RG6505, Roche's Phase 1 pan-RAS inhibitor. The study targets patients with MTAP-deleted, RAS-mutant pancreatic ductal adenocarcinoma.

IDEAYA will sponsor the clinical trial while Roche will supply RG6505. Both companies will maintain joint governance to oversee the study and retain all commercial rights to their respective compounds.

MTAP deletion occurs in up to 40% of pancreatic ductal adenocarcinoma cases, according to the company's estimates. The collaboration agreement includes the possibility of evaluating a three-drug combination that would add IDE397, IDEAYA's MAT2A inhibitor currently in Phase 2 trials, subject to approval from both companies.

"This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high unmet need in PDAC," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences.

IDEAYA plans to initiate Phase 1 combination studies of IDE892 with RG6505 in pancreatic cancer, as well as combinations with IDE397 in non-small cell lung cancer and other solid tumors. The South San Francisco-based company focuses on precision medicine oncology and targeted therapeutics development.

The information is based on a company press release statement.